BY Fraser Tennant
In its ‘Global M&A Review: First Half 2016’, Dealogic reveals that the total M&A value seen in the first half (1H) of 2016 was $1.71 trillion – an impressive figure in itself, although it represents an 18 percent year-on-year drop, from $2.09 trillion.
In terms of the key regional headline data, US targeted M&A volume was $748.5bn – down 18 percent year-on-year. Looking to Europe, the Middle East and Africa (EMEA), targeted M&A volume was $428.4bn, down 14 percent year-on-year and the lowest 1H total since 2011 ($67.1bn).
As far as global cross-border M&A volume is concerned, the review found that cross-border activity in 1H 2016 is valued at $580.9bn, down 6.6 percent year-on-year from $616.4bn. Furthermore, the US was the leading target accounting for 35 percent of volume ($205.8bn), up 39 percent year-on-year ($148.4bn) and the highest 1H volume on record.
In terms of Asia Pacific M&A, China accounted for 54 percent of targeted volume with $243.9bn – its highest 1H share on record and a record 21 percent share as an acquiring nation.
Leading the M&A adviser rankings is Goldman Sachs with transactions totalling $438.7bn, followed by Morgan Stanley on $330.0bn and Bank of America Merrill Lynch on $299.1bn.
Technology was the top sector with a total of $294.8bn, which was the second highest 1H volume on record (trailing the $304.6bn 1H volume seen in 2000). Conversely, the Telecom sector saw the biggest year-on-year drop among the top 10 sectors in 1H M&A deal volume – down some 70 percent from the $200.5bn seen in 1H 2015 to $60.7bn.
The Dealogic review also showcases the ‘Top 10 Announced M&A Transactions 1H 2016’ with Bayer’s $62.0bn bid for Monsanto in May 2016 top of the list.
Second on the list is the $48bn acquisition of Syngenta by China National Chemical Corp (ChemChina) in February 2016, the largest ever cross-border transaction by a Chinese acquirer. In third place is the April 2016 deal which saw Abbot Laboratories acquire St Jude Medical for $30.6bn.
Finally, the Dealogic data confirms that the total value of withdrawn M&A in 1H 2016, at $606.4bn, was more than double the same period in 2015 at $233.3bn. These withdrawn deals include the aborted transactions involving Energy Transfer Equity/Williams Companies in June 2016 and Pfizer/Allergan in April 2016.